Cytosorbents Corporation

What they do

CytoSorbents makes and sells CytoSorb, a cartridge filled with polymer beads that remove toxins from blood, used in ICUs and cardiac surgery. It is approved in the EU and distributed in over 70 countries, with nearly 300,000 devices used cumulatively. The company is also developing DrugSorb-ATR, an investigational device for the U.S. and Canada to reduce bleeding in high-risk surgery. CytoSorb is not yet approved in the U.S., but holds FDA Emergency Use Authorization for COVID-19.

Revenue drivers

• Direct sales in Germany — Largest single market, but sales declined in Q2 2026 due to a smaller, more focused sales force; management plans to add 3-5 reps to restore coverage.
• Direct sales outside Germany — Grew in Q2 2026, contributing to overall revenue, and is a focus for expansion.
• Distributor and strategic partner territories — Strong growth in Q2 2026, reflecting international demand for CytoSorb; these channels are key to revenue diversification.

Recent performance

Q2 2026 revenue was $9.6 million, unchanged from a year ago. Gross margin improved to 73% from 71% a year ago, and operating loss improved by 27% to $2.6 million. Net loss was $4.4 million ($0.07 per share) versus net income of $1.9 million in Q2 2025, driven by non-cash foreign currency translation changes. Adjusted net loss (excluding those and stock comp) improved 22% to $2.8 million. Cash burn was $0.4 million, including restructuring payments, and total cash was $5.9 million at quarter end.

Strategy

Management aims to achieve operating cash flow breakeven in the second half of 2026, cutting costs and improving margins. They reduced workforce by ~23% since September 2025 and are streamlining commercial execution and working capital. They plan to add 3-5 sales reps in Germany by early 2027 to restore full coverage. They are also advancing regulatory programs, notably DrugSorb-ATR with two FDA Breakthrough Device Designations, and focusing on four independent value drivers: cash flow breakeven, and others mentioned in the release.

Risks

• Cash and liquidity — Cash was only $4.4M (total cash $5.9M) at June 30, 2026, with negative shareholder equity of -$751,000, raising going-concern risk.
• Germany sales decline — A smaller sales force in Germany, the company's largest market, has reduced revenue, and recovery depends on hiring.
• U.S. approval uncertainty — DrugSorb-ATR is investigational in the U.S. and Canada; no FDA approval yet, and delays would limit access to a key market.
• Delisting risk — Received delisting notices in April and July 2026, indicating potential Nasdaq listing-rule failures.

Outlook

Management expects to achieve operating cash flow breakeven in the second half of 2026, with Q2 cash burn down to ~$200K excluding restructuring. They plan to hire 3-5 sales reps through early 2027. They cite four independent value drivers over the next 6-18 months that could strengthen the business, but caution that they are not yet where they want to be.